OVP Venture Partners

...cell research practical for the pharmaceutical industry, reeled in $30 million in a Series B round of venture financing. Kirkland, WA-based OVP Venture Partners led the new round of investment in Fate, which was founded by top academics at...

In this article: Harvard University, Amgen, First Round Capital, Polaris Venture Partners, Highland Capital Partners, and Broad Institute

I also recapped some of Trubion's latest tribulations, to give a sense of what Thompson is leaving to his successor. Kirkland, WA-based OVP Venture Partners wanted a bigger piece of the original action in San Diego-based Fate Therapeutics,...

In this article: Seattle, Cancer, Eli Lilly, Harvard, Nasdaq, NanoString Technologies, and Broad Institute

...contributed to a $30 million Series B venture financing round for San Diego-based stem cell startup Fate Therapeutics. Kirkland, WA-based OVP Venture Partners led the deal, which also involved Arch Venture Partners, Venrock Associates,...

In this article: Genzyme, Nasdaq, FDA, Iphone, Alkermes, Mipomersen, Atorvastatin, and Phosphate

...(or longer), the Northwest erupted with a slew of financings in the past week. -But first, some serious biotech. Kirkland, WA-based OVP Venture Partners led a $30 million Series B round for Fate Therapeutics, a San Diego-based stem...

In this article: Seattle, DocuSign, Redfin, San Diego, Zino Society, Genzyme Ventures, and Jafco Ventures

...-- Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture...

In this article: California, Astellas Venture Management, ARCH Venture Partners, Genzyme Ventures, and Polaris Venture Partners

...Washington. In fact, when Fate was founded more than two years ago, there was hope that the company would be based in the Seattle area. But the company later tapped venture capitalist Paul Grayson as CEO, and Fate later established its...

In this article: Seattle, California, Astellas Venture Management, Genzyme Ventures, Polaris Venture Partners, Venture capital, and Seattle Post-Intelligencer

...practical for the pharmaceutical industry, has raised $30 million in a Series B round of venture financing. Kirkland, WA-based OVP Venture Partners led the deal, which included the three venture firms that co-founded the company two...

In this article: Astellas Venture Management, San Diego, Genzyme Ventures, Polaris Venture Partners, Cancer, The Scripps Research Institute, and University of Washington

...chemical company to raise capital from VCs lately. Ithaca, N.Y.-based Novomer raised $14 million in a Series B round this summer from OVP Venture Partners, Physic Venture Partners, Flagship Venture Partners and DSM Venturing. The...

In this article: Succinic acid, Versant Ventures, Joint venture, CMEA Ventures, Mitsui & Co., and Department of Energy

...innovative ideas, and a VC community very committed to fostering growth. Mark Ashida is a managing director at Kirkland, WA-based OVP Venture Partners. He focuses on investments in infrastructure, software as a service, networking, and...

In this article: Venture capital, Seattle, Recession, Voyager Capital, and Ignition Partners

Friday, October 30, 2009, 5:13pm PDT Early-stage tech venture capital firm OVP Venture Partners is relocating to downtown Portland after 25 years outside the city core. OVP is leaving its space in Johns Landing for the Umpqua Bank...

In this article: Portland, Venture capital, Lake Oswego, Hillsboro, and Oregon